Form 8-K

0001171843-21-005839.txt : 20210811 0001171843-21-005839.hdr.sgml : 20210811 20210811161606 ACCESSION NUMBER: 0001171843-21-005839 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210811 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210811 DATE AS OF CHANGE: 20210811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zomedica Corp. CENTRAL INDEX KEY: 0001684144 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38298 FILM NUMBER: 211163604 BUSINESS ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: (734) 369-2555 MAIL ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: Zomedica Pharmaceuticals Corp. DATE OF NAME CHANGE: 20160908 8-K 1 f8k_081121.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2021

_______________________________

ZOMEDICA CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Alberta, Canada	001-38298	N/A
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Phoenix Drive, Suite 125

Ann Arbor, Michigan 48108

(Address of Principal Executive Offices) (Zip Code)

(734) 369-2555

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, without par value	ZOM	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2021, Zomedica Corp. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2021. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release, dated August 11, 2021.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZOMEDICA CORP.


Date: August 11, 2021	By:	/s/ Ann Marie Cotter
		Ann Marie Cotter
		Chief Financial Officer

EXHIBIT INDEX

99.1		Press Release, dated August 11, 2021.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Zomedica Announces Second Quarter 2021 Financial Results

TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales

ANN ARBOR, Mich., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and six months ended June 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Robert Cohen, Chief Executive Officer of Zomedica stated that, “I fully understand and appreciate that what all of our stakeholders, both internal and external, want to see is continued execution on our goals and the building of increased value in our business. For quite some time now, we have been focused on executing on the many behind the scenes activities necessary to advance and grow a young company. After a delay due, in part, to the unexpected sale of our distribution partner and the lack of completion of the fT4 and ACTH assays from our development partner, we have implemented a new plan to place TRUFORMA^® Instruments in veterinary clinics. That program -- named our Customer Appreciation Program -- provides interested customers with a TRUFORMA^® Instrument pursuant to a written agreement under which the customer agrees to purchase assay cartridges for use on that Instrument. Our intent not only is to sell cartridges to be used on these Instruments, but also to establish an installed base of TRUFORMA^® Instruments so that assays available in the future can be added to their then-existing usage, similar to a razor/razor blade model. From July 13^th, when we began the program, to yesterday, we have secured 41 signed Instrument placement agreements and have installed 25 TRUFORMA^® Instruments under our Customer Appreciation Program. These installations tend to lag approximately one to two weeks behind the signature of an agreement. We are likely to continue the Customer Appreciation Program until the availability of the fT4 assay.”

Mr. Cohen continued, “Our business development efforts also are continuing. We have evaluated many opportunities, and intend to carefully evaluate all opportunities that we or others bring to Zomedica. Potential structures of interest to the Company range from acquisition to distribution of third-party products to minority investment to securing the rights to developing technologies, all with the intended goal of enhancing the value of Zomedica by providing additional high-quality products to our direct sales organization and additional value to both our installed base of customers and new customers. With the continued growth in the animal health market, we believe that now is an opportune time to expand our product offerings in this exciting industry.”

“To support TRUFORMA^®, our sales organization now has grown to include 10 Regional Diagnostic Specialists and Territory Diagnostic Specialists, 3 Professional Services Veterinarians, and 2 Inside Sales Representatives, all supported by a Customer Service Department and managed by our Chief Commercial Officer, Vice President of Sales, and two Area Sales Directors. We continue to recruit additional members of the sales organization and expect to have our sales and support teams at full planned strength by the end of the Fall. We believe that this team is capable of supporting not only TRUFORMA^®, but also any additional products that are added to Zomedica.”

Summary Second Quarter 2021 Results

Zomedica reported a net loss for the three and six months ended June 30, 2021 of approximately $4.7 million, or $.005 per share, and approximately $8.7 million, or $0.01 per share, respectively, compared to a net loss of approximately $5.3 million, or $0.02 per share, for the three months ended June 30, 2020, an increase in income of approximately $0.6 million, or 11% and a net loss of approximately $7.8 million, or $0.05 per share for the six months ended June 30, 2020, a decrease in income of approximately $0.9 million, or 13%.

Revenue for the three and six months ended June 30, 2021 was $15,693 and $29,817, respectively, and resulted from the sale of our TRUFORMA^® products and associated warranties. We commenced commercialization of TRUFORMA^® on March 15, 2021 and, accordingly, had only limited sales activity in the first and second quarters of 2021.

The Company believes that market acceptance of TRUFORMA^® has been adversely impacted by delays in the development of our fT4 and ACTH assays by our development partner. We expect that market adoption of TRUFORMA^® will be challenging until our fT4 and ACTH assays are available for commercial release. We expect that the fT4 assay will be available for commercial sale in the fall of 2021 and that the ACTH assay will be available for commercial sale by the end of 2021.

Cost of revenue for the three and six months ended June 30, 2021 was $35,876 and $41,533, respectively. As noted above, commercialization of TRUFORMA^® commenced on March 15, 2021. The Company expects that cost of revenue will increase as we sell additional products in subsequent periods.

Research and development expense for the three and six months ended June 30, 2021 was approximately $0.3 million and approximately $0.7 million, respectively, compared to approximately $3.9 million and $4.5 million for the three and six months ended June 30, 2020, respectively, representing a decrease of approximately $3.6 million, or 93%, over the prior three-month period and a decrease of approximately $3.1 million, or 85%, for the prior six-month period. The decrease in both periods was a result of an overall reduction in research and development activity as the Company curtailed our drug development activities, and a reduction in development costs related to TRUFORMA^® as the Company completed development of the instrument and three of the first five assays and began transitioning to commercialization activities.

Selling, general and administrative expense for the three months ended June 30, 2021 was approximately $5.0 million, compared to approximately $1.4 million for the three months ended June 30, 2020, an increase of approximately $3.6 million, or 261%. The increase primarily was due to an increase in share-based compensation expense which was approximately $1.7 million for the three months ended June 30, 2021, compared to approximately $0.1 million for the comparable period in 2020. Other significant increases include regulatory fees incurred for the annual shareholders meeting of approximately $0.9 million, salaries of approximately $0.6 million, professional fees of approximately $0.3 million, contracted expenditures of approximately $0.1 million, and marketing, travel and office expense of $0.1 million.

Liquidity and Outstanding Share Capital

Zomedica had cash and cash equivalents of approximately $276.2 million as of June 30, 2021, compared to approximately $29.1 million as of June 30, 2020. The increase in cash during the three months ended June 30, 2021 is mainly a result of the cash flows from financing activities, partially offset by cash flows used in operating and investing activities as discussed below.

As of June 30, 2021, Zomedica had shareholders’ equity of approximately $276.1 million. After giving effect to exercises of warrants and stock option exercises in July 2021, as of August 11, 2021, Zomedica’s pro forma shareholders’ equity as of June 30, 2021 would have been approximately $276.4 million.

Net cash used in operating activities for the six months ended June 30, 2021 was approximately $4.4 million, compared to approximately $7.9 million for the six months ended June 30, 2020, a decrease of approximately $3.5 million, or 45%. Approximately $3.0 million of current period expense is non-cash expense associated with stock compensation, recorded as a result of stock option grants in 2020, compared to the prior period of approximately $0.3 million, approximately $0.5 million in gains recognized on extinguishment of debt, and a loss on disposal of property of $0.2 million. Other non-cash activity included amortization and depreciation of approximately $0.2 million. Accounts payable increased by approximately $1.9 million, offset in part by an increase in inventory purchases of approximately $0.8 million.

Net cash used in investing activities for the six months ended June 30, 2021 was approximately $0.1 million, compared to net cash provided of approximately $1.0 million for the six months ended June 30, 2020, an increase in net cash used of approximately $1.1 million, or 114%. The increase in net cash used in investing activities was due to the receipt of cash from the modification of our lease in the first half of 2020 compared to investments of intangible and other property and equipment in the current period.

Net cash from financing activities for the six months ended June 30, 2021 was approximately $218.7 million, compared to approximately $35.5 million for the six months ended June 30, 2020, an increase of approximately $183.2 million, or 517%. The increase resulted primarily from the sale of our equity securities for total gross proceeds of approximately $199.5 million, cash received of approximately $32.1 million from warrant exercises, and cash received of approximately $1.4 million from stock option exercises, offset by stock issuance costs of approximately $14.3 million.

As of June 30, 2021, Zomedica had an unlimited number of authorized common shares with 977,950,993 common shares issued and outstanding. As of August 11, 2021, Zomedica had 979,728,168 common shares issued and outstanding.

For complete financial results, please see Zomedica’s filings on EDGAR and SEDAR or visit the Zomedica website at www.ZOMEDICA.com.

For additional information regarding TRUFORMA^®, please click on the TRUFORMA^® tab at the top of the home page on the Zomedica website (www.zomedica.com).

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica

Reader Advisory
Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
PCG Advisory
Kirin Smith, President
ksmith@pcgadvisory.com
+1 646.823.8656

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_081121_htm.xml IDEA: XBRL DOCUMENT 0001684144 2021-08-11 2021-08-11 iso4217:USD shares iso4217:USD shares 0001684144 false 8-K 2021-08-11 ZOMEDICA CORP. A0 001-38298 100 Phoenix Drive, Suite 125 Ann Arbor MI 48108 734 369-2555 false false false false Common Shares, without par value ZOM NYSEAMER true true XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 11, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 11, 2021
Entity File Number	001-38298
Entity Registrant Name	ZOMEDICA CORP.
Entity Central Index Key	0001684144
Entity Incorporation, State or Country Code	A0
Entity Address, Address Line One	100 Phoenix Drive, Suite 125
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48108
City Area Code	734
Local Phone Number	369-2555
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	ZOM
Security Exchange Name	NYSEAMER
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /"!"U,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #P@0M3&7]+G^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VE1)'1S43PI""XHWD(RNQMLTI",M/OVMG&WB^@#>,S,GV^^ M@>E,E&9(^)R&B(DX2&\QOP2-IJTK J[@2F>JLD2:AIB&=\-:L^/B9^@*S!K!'CX$RB%H 4\O$ M>)SZ#BZ !4:8?/XNH%V)I?HGMG2 G9)3=FMJ',=Z;$MNWD' V]/C2UFW&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M\($+4X8AILH\! -Q !@ !X;"]W;W)KH%OG_M94S(SFA87IOKT5 5-A62SS4Q198Q_7[/ M4[6]Z]#.X<)";!+K+GBC8[;O M=TA4&*NR?3 09$+N?MG;/A%' =WNB8!@'Q"4W+L7E90/S++14*LMT>YI4',' MY5#+:( 3TLW*TFJX*R#.CL;JE>NA9T'*7?"B?=C]+BPX$186FRM"Z04)_(#^ M.]P#@@HCJ#""4J^+89 _PY6Q&B;J+T2R6TEV2\G>"\:81X M^.#R$P+1JR!ZJ$H(!'%)\9BR31,%'K]FJ>$(1[_BZ)^7C#G70L5D(F,"]=*8 M%USI,/,_??C0,O?7%=LUJCB15MAW\BA23IZ*;-539YF(Y#,GY>S*\0L$$%-C@'; SSJ%E*IC+F M;^03?V]"PY5\R-?UH$=[/03KML*Z/0=K*B.E",/&I86 M&',A8,PTZ&/,1\Y,?XAY[,X@H2]J*QMY<;E02A+JE=(87.W7-/@AN&JZYUJ] M"ADU9Q37G$TQM-KW*>[<_T6;*V/A<_DF\I,UV*+8&U ?DCII$*%VI;,VF]$%#:7T:0'@[?UVYK [L+V#<]K]A:!&#S@8$<[HH3)#3^Y M&6H1>OIC.0EGDP5&55M\<);%3S*N-RY-OX*"39QUY$PV3RHN:#4^<;7!![@_ M3UR[R6/RI.#K5.2+X<0F'+)GW9<0$YA8Z&C+AG2W%6^$Q=]Q"M8[:@-=2SUC M+CN&I'P-.O[5#;BYWG6INQ.K\K(S7"D+?69YF$!GS[5[ .ZOE;*'$]=L5O\K M&/T#4$L#!!0 ( /"!"U.?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0& M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&- M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+ MY2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'D ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^ M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM! M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7 M,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( /"!"U.7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_081121.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_081121.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_081121.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_081121.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_081121.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001171843-21-005839-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-21-005839-xbrl.zip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end